Table 1.

Prevalence of PD-L1 expression in human cancers

Tumor histologyPercent tumor samples expressing PD-L1Tumor surface expression cutoff for positivityPD-L1 detection antibodyReferences
Melanoma45%5%28-8(76)
100%>10%5H1(24)
91%NRR&D B7-H1(37)
38%5%5H1(54)
77%1%NR(70)
RCC44% (primary tumor), 54% (metastasis)10%5H1(77)
24%5%5H1(22)
14%5%405.9A11(78)
24%H-score >05H1(79)
NSCLC49%5%28-8(76)
52%NRR&D B7-H1(37)
95%>10%5H1(24)
50%11%MIH1(80)
21% (squamous only)>1% vs. >5% vs. H-score5H1(50)
60%5%DAKO IHC(71)
50%1%NR(81)
Bladder21% (37% squamous, 22% transitional)5%28-8(38)
28%1%5H1(82)
20%5%405.9A11(83)
Head and neck31%5%28-8(38)
66%10%5H1(84)
Cervical29%5%28-8(38)
19%NR5H1(64)
Glioblastoma multiforme25%5%28-8(38)
45%50%NR(85)
Breast cancer18% TNBC (0% ER/PR/HER2+)5%28-8(38)
43% overall (59% TNBC)NRR&D B7-H1(37)
50%1%MIH1(86)
Gastric42%NR2H11(87)
Esophageal20%5%28-8(38)
44% (squamous)10%MIH1(88)
Hepatocellular carcinoma15%5%28-8(38)
25%NReBioscience anti-B7-H1(89)
Pancreatic39%10%MIH1(90)
Colorectal53%>10%5H1(24)
56% (MSI-H) vs. 21% (MSS)NRCaris(42)
Thymic cancer100% (thymoma), 88% (thymic carcinoma)NR29E (.5A9/.2A3)(91)
100% (thymoma and thymic carcinoma)NRSino clone 15(92)
Ovarian87%>10%5H1(24)
89%5%27A2(20)
Sarcoma12% (27% GIST)1%DAKO PD-L1 IHC(28)
Unknown primary28%5%28-8(38)
Acute myeloid leukemia37%5%MIH1(93)
Leukemias (various)57%NR5H1(94)
B-cell lymphomas58%5%DFCI 339.7G11(27)
Multiple myeloma93%NRN20 antihuman PD-L1(59)

Abbreviations: ER, estrogen receptor; H-score, immunoreactivity score: (3 × percentage of strongly staining tumor cells) + (2 × percentage of moderately staining tumor cells) + (percentage of weakly staining tumor cells), range of 0 to 300; NR, not reported; PR, progesterone receptor.